Calzada UD, Vasallo DAL, Heredia MB

Language: Spanish
References: 11
Page: 449-455
PDF size: 210.62 Kb.

ABSTRACT

Adrenal carcinoma is a rare devastating tumor, mainly because in most cases it is in advanced stages at the time of diagnosis. It has an incidence of 0.5-2 cases per one million inhabitants per year, in which 40 to 70 % of patients have metastases when the study begins. It occurs mainly in adults, although it also affects children. The median age at the time of diagnosis is 46 years, being more frequent in males. The case of a patient with a history of arterial hypertension of one year of evolution is presented. In view of the symptoms presented, imaging and laboratory studies are performed, diagnosing a left adrenal tumor. A left supraadrenelectomy was performed, obtaining an adenocortical adrenal carcinoma as a histopathological result.

REFERENCES

1. Niederhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE. Abeloff Oncología Clínica. 6ta ed. Estados Unidos:Elsevier;2020.

2. Vilchis MA, López JF, Aragón AR, Torres E, Saldaña MJ, García MA, et al. Carcinoma de corteza suprarrenal, informe de un caso y revisión de la bibliografía. Rev Mex Urol[Internet]. 2011[citado 23 Ene 2021];71(1):[aprox. 9p.]. Disponible en: https://www.elsevier.es/es-revista-revista-mexicana-urologia-302-articulo-carcinoma-corteza-suprarrenal-informe-un-X2007408511009661.

3. Martin AE, Serrano JE. Tumores de la glándula suprarrenal. En: Rivera S. Oncología General para profesionales de salud de primer impacto. Mexico:Sociedad Mexicana de Oncología;2017. p 160-3.

4. Valton N, Velásquez S, Creagh IM. Carcinoma de la corteza suprarrenal. Presentación de un caso. Rev Inf Cient[Internet]. 2018[citado 5 May 2021];97(1):[aprox. 8p.]. Disponible en: https://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1028-99332018000100166&lng=es.

5. Betancourt VC, Archila EI. Tumores suprarrenales. Revisión bibliográfica. Act Med Cent[Internet]. 2014[citado 5 May 2021];8(1):[aprox. 4p.]. Disponible en: https://www.revactamedicacentro.sld.cu/index.php/amc/article/vieu/59/158.

6. Amin MB, Edge SB, Greene FL. Adrenal Cortical Carcinoma. AJCC Cancer Staging Manual. 8th ed. España:Springer;2017.

7. Polanía D, García J, García C, Ruiza PC, Mejía OM. Carcinoma corticoadrenal. Revisión del tema. Rev Fac Med[Internet]. 2011[citado 5 May 2021];19(2):[aprox. 9p.]. Disponible en: https://www.scielo.org.co/scielo.php?script=sci_abstract&pid=S0121-52562011000200007&lng=es&nrm=is.

8. Ammar A, Anish J, Patel R, Thomas W, Courtney J, Balentine C. Tumores del sistema endocrino. En: Niederhuber JE, Armitaje JO. Abeloff. Oncología Clínica. España: Elsevier;2020. p 1074-107.

9. Zapata A, Galleguidos M, García V, Espinosa P, Ablan F, Valenzuela J, et al. Síndrome de Cushing provocado por carcinoma suprarrenal gigante. Caso clínico. Rev Med Chile[Internet]. 2020[citado 11 Feb 2021];148(11):[aprox. 15p.]. Disponible en: https://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872020001101679.

10. Fassnacht M, Dekkers O, Else T, Baudin E, Berruti A, de Krijger R, et al. European Society of Endocrinology Clinical Practice Guidelines of the Management of Adrenocortical Carcinoma in Adults, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2018;179(4):G1-G46.

11. Tang Y, Liu Z, Zou Z, Liang J, Lu Y, Zhu Y. Benefits of adjuvant mitotane after resection of adrenocortical carcinoma: A systematic review and meta-analysis. Biomed Res Int. 2018;93(62):108.